One dose of an experimental gene treatment lowered LDL Cholesterol by an average of 62% at the highest dose tested. The treatment, VERVE-102, aims to switch off a gene in the liver. That gene makes PCSK9, a protein involved in controlling LDL Cholesterol. Researchers tested it in 35 adults. They had inherited high cholesterol or heart artery disease at a young age. Each person received one dose through a vein. Six dose levels were tested, and everyone knew they received the treatment. Average cholesterol drops ranged from 9% at the lowest dose to 62% at the highest. At the highest dose, the average drop was 78 mg/dL. Blood levels of the targeted protein fell by 51% to 88%. The drops appeared to last throughout follow-up. Everyone was followed for at least 28 days; 15 people reached at least one year. These are promising early results, not proof of lifelong benefit. The study was small and had no untreated comparison group. It did not establish whether treatment prevents heart attacks. Side effects included mild-to-moderate reactions during or around the infusion. Temporary rises in ALT (Alanine Aminotransferase), a liver blood marker, also occurred. One person with acid reflux developed lung irritation after breathing in stomach contents. No harmful effects prevented further dose increases. For BioSocial members, the useful tracking lesson is to look beyond one percentage. Starting levels, the size of a drop, and repeat results all matter. Sharing dated bloodwork and notes about routine changes can make community comparisons more useful. This experimental treatment is not an everyday health habit. What changes have you seen in your own numbers, and how long have those changes lasted?